COMMUNIQUÉS West-GlobeNewswire

-
Transactions under Novozymes’ stock buyback program
29/07/2019 -
Ziopharm Oncology Announces $45 Million Warrant Exercise by Existing Shareholders in a Private Placement
29/07/2019 -
Allogene Therapeutics to Report Second Quarter 2019 Financial Results on August 7, 2019
29/07/2019 -
Turning Point Therapeutics Appoints Biotechnology Investment Banker Yi Larson as Executive Vice President and Chief Financial Officer
29/07/2019 -
TRACON Pharmaceuticals to Participate in Wells Fargo Securities 2019 Biotech Corporate Access Day
29/07/2019 -
VBI Vaccines Announces Dosing of First Recurrent GBM Patient in Part B of Ongoing Phase 1/2a Study of VBI-1901
29/07/2019 -
TYME Technologies Announces New Collaboration with NYU Langone to Advance TYME’s Cancer Metabolism-Based Therapy, SM-88
29/07/2019 -
AMAG Pharmaceuticals to Host Second Quarter 2019 Financial Results Conference Call and Webcast on Wednesday, August 7, 2019 at 8:00 a.m. ET
29/07/2019 -
Aggressive Growth by Commercial Medical Device Reprocessors Saved Hospitals and Health Systems Nearly $500M Last Year, According to 20th Anniversary Report from Association of Medical Device Reprocessors
29/07/2019 -
Biotricity Audited Year-End Results Demonstrate Execution of Commercial Growth Plans
29/07/2019 -
H-CYTE Bolsters Board of Directors With Appointment of Dr. Andre Terzic to Board of Directors
29/07/2019 -
Athenex, Inc. to Report Second Quarter 2019 Earnings Results on August 7, 2019
29/07/2019 -
Rhythm Pharmaceuticals Announces Positive Opinion by the European Medicines Agency on Orphan Drug Designation for Setmelanotide for the Treatment of Bardet-Biedl Syndrome
29/07/2019 -
Ascendis Pharma A/S Announces Participation in August Investor Conferences
29/07/2019 -
Avinger Announces Pantheris SV Limited Launch and Successful Treatment of First Patients in the United States
29/07/2019 -
Appendix 4C– June 2019 Quarter
29/07/2019 -
Spring Bank Announces FDA Acceptance of IND Application for SB 11285, an IV-Administered STING Agonist, for the Treatment of Advanced Solid Tumors
29/07/2019 -
Crinetics Pharmaceuticals to Receive Final Award of SBIR Grant from NIH for Congenital Hyperinsulinism
29/07/2019 -
Alkahest Phase 2a Study AKST4290-202 in Refractory Neovascular AMD meets Primary and Secondary Endpoints
29/07/2019
Pages